Navigation Links
Entest BioMedical Inc. Adds Former National Cancer Institute Researcher to Scientific Advisory Board With Focus on Stem Cell Cancer Patient Therapies
Date:6/8/2009

SAN DIEGO, June 8 /PRNewswire-FirstCall/ -- Dr. Steven Josephs, Ph.D., a former National Cancer Institute (NCI) researcher, has joined Entest BioMedical Inc.'s (www.entestbio.com) Science Advisory Board where he will focus on expanding the company's stem cell cancer research. Dr. Josephs' NCI research involved studies of the human T-cell leukemia virus, HIV and Human Herpervirus-6 genetic characterization. Josephs also worked for Baxter Healthcare and GenStar Therapeutics where he focused on the cellular and molecular biology of gene therapy for hemophilia. Entest BioMedical Inc. is a wholly-owned subsidiary of San Diego-based Bio-Matrix Scientific Group Inc. (OTC Bulletin Board: BMSN; www.BMSN.us).

According to David Koos, Chairman and CEO of both Entest BioMedical Inc. and Bio-Matrix Scientific Group Inc., "Dr. Josephs' extensive cancer research background adds strength to our growing Scientific Advisory Board. His insight into potential stem cell therapies for cancer patients will help expedite Entest BioMedical's goal of providing innovative stem cell transplantation therapies and services including autologous and allogenic peripheral blood or bone marrow transplantation.

Dr. Feng Lin, Director of Research for Entest BioMedical and Bio-Matrix Scientific Group, also applauded the addition of Dr. Josephs' to the Science Advisory Board. "Dr. Josephs joins our life science team at exactly the right time," said Lin. "We're currently interested in differentiating hematopoietic stem cells into immune cells especially T-cells. Dr. Josephs will work with us on our research goal of generating a new population of immune cells from a patient's own stem cells to reactivate the patient's immune system. This strategy represents a novel and effective immunotherapy especially for cancer patients and HIV patients who have injured immune systems and are at high risk of infection with bacteria and viruses."

About Entest BioMedical Inc.:

Entest BioMedical, Inc., a wholly-owned subsidiary of Bio-Matrix Scientific Group, Inc. (OTC BB: BMSN) formed in April 2009, focuses on research and development of traumatic brain injury (TBI) and spinal cord injury using autologous 'adipose-derived' stem cells. Entest BioMedical is involved with R&D activities relating to stem cell therapies, diabetes testing and medical devices.

About Bio-Matrix Scientific Group Inc.:

Bio-Matrix Scientific Group Inc. (OTCBB: BMSN) is a San Diego, California based biotechnology research and development company with a 15,000 square foot facility that houses two secure cryogenic stem cell banks, three research laboratories, aseptic cellular/tissue class 10,000/100 processing lab, hematology, microbiology and flow cytometry laboratories.

Disclaimer:

This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.


'/>"/>
SOURCE Bio-Matrix Scientific Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Bio-Matrix Scientific Group and Entest BioMedical Sign Contract With UCLA Researcher to Develop Gestational Diabetes Screening Test
2. New Video Series Spotlights Role of Biomedical Engineers in Caring for Total Artificial Heart Patients
3. Response Biomedical Closes $12.65 million Unit Offering
4. Garth Fisher, M.D., F.A.C.S., World Renowned Plastic Surgeon and Co-Founder Of CellCeuticals(R) Biomedical Skin Treatments Revealed On E!s Keeping Up With The Kardashians as the Surgeon Behind Bruce Jenners New Face
5. Response Biomedical Announces Proposed Unit Offering
6. Dr. Abbott J. Krieger Joins Avery Biomedical Devices, Inc. as Chief Clinical Liaison
7. Response Biomedical Corporation Delivers Record Preliminary Revenues in First Quarter
8. BioMedical Technology Solutions, Inc. a Division of BioMedical Technology Solutions Holdings, Inc. Symbol (BMTL) OTCBB Receives Frost & Sullivans Product Innovation of the Year Award
9. Foundation for Biomedical Research Announces Michael E. DeBakey Journalism Awards
10. Response Biomedical Corporation Reports 2008 Financial Results
11. Advance Internet Launches HireBioMedical.com
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... ... announced its strategic partnership with Connance, a healthcare industry leader providing predictive ... proven, proprietary technology combine to provide health systems, hospitals and ambulatory surgical ...
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ... , "Film editors can give their videos a whole new perspective by using the ... CEO of Pixel Film Studios. , ProSlice Levels contains over 30 Different presets ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs ... College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. ... treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. ...
(Date:6/25/2016)... City, Oklahoma (PRWEB) , ... June 25, 2016 ... ... helping both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic ... the Oklahoma City area —Johnson is one of the first doctors to perform ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016  Global Blood Therapeutics, Inc. (GBT) (NASDAQ: ... novel therapeutics for the treatment of grievous blood-based ... closing of its previously announced underwritten public offering ... public offering price of $18.75 per share. All ... by GBT. GBT estimates net proceeds from the ...
(Date:6/24/2016)... BEIJING , June 24, 2016 Dehaier ... or the "Company"), which develops, markets and sells medical ... China , signed a strategic cooperation agreement with ... as "Hongyuan Supply Chain") on June 20, 2016, to ... Under the strategic cooperation agreement, Dehaier will leverage Hongyuan ...
(Date:6/24/2016)... NAMUR , Belgium , ...  (NYSE MKT: VNRX), today announced the appointment of ... Board of Directors as a Non-Executive Director, effective ... the Company,s Audit, Compensation and Nominations and Governance ... Board, Dr. Futcher will provide independent expertise and ...
Breaking Medicine Technology: